Splenic sequestration crisis in children with sickle cell disease in the Eastern region of Saudi Arabia
- PMID: 40887585
- PMCID: PMC12400761
- DOI: 10.1186/s12887-025-06020-w
Splenic sequestration crisis in children with sickle cell disease in the Eastern region of Saudi Arabia
Abstract
Background: Acute splenic sequestration crisis (ASSC) is a potentially life-threatening complication of sickle cell disease (SCD). Previous studies have shown that patients who carry the African sickle gene haplotypes have more severe SCD than those with the Asian haplotype. In Saudi Arabia (SA), people living in the eastern region are known to carry the Asian haplotype, whereas patients in the southwestern (SW) region are more likely to carry the African haplotype. The aim of this study was to determine the prevalence and clinical features of ASSC among children with SCD who originated from both regions but were living in the same environment in the eastern region of that country.
Methods: This retrospective cohort study included 340 children with SCD who visited our hospital from 2010 to 2020. The collected clinical data of patients with ASSC were compared between two groups of patients: eastern and SW children.
Results: Over the study period, out of 340 children with SCD, 50 patients had ASSC, with a male/female ratio of 2.1:1. There were 38 children from the SW region and 12 from the eastern region. The overall prevalence of ASSC was 14.7%, with no significant difference between the two groups (p = .56). The SW group was diagnosed with SCD at a younger age than their eastern peers [median (IQR)]: 8.5 (6-11) vs. 30.5 (24-36) months; p < .001. The median (IQR) steady state hemoglobin (HB) level in the SW group was significantly lower than that in the eastern group [8 (7.5-9) vs. 9 (8-10) gm/dL]; p = .001]. During the first instance of episode of ASSC, there was a significant difference between the SW group and the eastern group in the following parameters [median (IQR)]: age [25 (12-48) v. 72 (39-134) months, p = .001], HB [5.1 (4.4-5.9) v. 6.1 (5.9-6.4) gm/dL, p = .01], splenic size on admission [5.5 (3-8) v. 8 (6-9.5) cm, p = .01], and splenic size upon discharge [3 (2-5) v. 5 (3.5-5.5) cm below the costal margin, p = .02]. The SW group had a significantly greater number of recurrences than did the eastern group [3.5 (2-6) v. 2 (1.5-2.5); p = .03].
Conclusions: The overall prevalence of ASSC among SCD children in the eastern region of SA was 14.7%, and there was no significant difference between the eastern and SW groups. Despite living in the same environment in the eastern region, children from southwestern SA experienced more severe ASSC manifestations than their eastern peers.
Trial registration: Not.
Keywords: Children; Eastern region; Saudi; Sickle cell disease; Splenic sequestration.
© 2025. The Author(s).
Conflict of interest statement
Declarations. Ethical approval and consent to participate: This study was conducted in accordance with good clinical practice and the declaration of Helsinki. The study received scientific and ethical approval from the Armed Forces Hospitals Eastern Province Institutional Review Board (IRB): IRB (Protocol No. AFHER-IRB-2021-008). A waiver of informed consent was granted due to the retrospective nature of the study. Consent for publication: Not applicable. Competing interests: The authors declare no competing interests.
Figures
Similar articles
-
Folate supplementation in people with sickle cell disease.Cochrane Database Syst Rev. 2018 Mar 16;3(3):CD011130. doi: 10.1002/14651858.CD011130.pub3. Cochrane Database Syst Rev. 2018. PMID: 29546732 Free PMC article.
-
Prescription of Controlled Substances: Benefits and Risks.2025 Jul 6. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 Jan–. 2025 Jul 6. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 Jan–. PMID: 30726003 Free Books & Documents.
-
Preoperative blood transfusions for sickle cell disease.Cochrane Database Syst Rev. 2016 Apr 6;4(4):CD003149. doi: 10.1002/14651858.CD003149.pub3. Cochrane Database Syst Rev. 2016. Update in: Cochrane Database Syst Rev. 2020 Jul 2;7:CD003149. doi: 10.1002/14651858.CD003149.pub4. PMID: 27049331 Free PMC article. Updated.
-
Hydroxyurea (hydroxycarbamide) for sickle cell disease.Cochrane Database Syst Rev. 2022 Sep 1;9(9):CD002202. doi: 10.1002/14651858.CD002202.pub3. Cochrane Database Syst Rev. 2022. PMID: 36047926 Free PMC article.
-
Hematological Characteristics of Patients With Sickle Cell Disease in Al Ahsa, Saudi Arabia.Cureus. 2025 Jul 7;17(7):e87432. doi: 10.7759/cureus.87432. eCollection 2025 Jul. Cureus. 2025. PMID: 40772168 Free PMC article.
References
-
- Namazzi R, John CC, Conroy AL, Datta D, Ware R, Hume H, et al. Development of research capacity in sickle cell anemia in Uganda: impact of collaborations. Blood Adv. 2017;1:11–3.
-
- Allali S, Galacteros F, Oevermann L, Cannas G, Joseph L, Loko G, et al. Hydroxyurea is associated with later onset of acute splenic sequestration crisis in sickle cell disease: lessons from the European sickle cell disease Cohort-Hydroxyurea (ESCORT-HU) study. Am J Hematol. 2024;99:555–61. - PubMed
-
- Kane I, Kumar A, Atalla E, Nagalli S. Splenic sequestration crisis. Treasure Island (FL): StatPearls Publishing; 2025. - PubMed
-
- Khaled MB, Ouederni M, Mankai Y, Rekaya S, Ben Fraj I, Dhouib N, et al. Prevalence and predictive factors of Splenic sequestration crisis among 423 pediatric patients with sickle cell disease in Tunisia. Blood Cells Mol Dis. 2020;80: 102374. - PubMed
-
- Serjeant G, Mason K, Hambleton I, Serjeant B. Acute splenic sequestration in hbss: observations from the Jamaican birth cohort. Arch Dis Child. 2024;109:100–5. - PubMed
MeSH terms
LinkOut - more resources
Full Text Sources
Medical